# A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II)

> **NCT05494593** · PHASE4 · WITHDRAWN · sponsor: **Takeda**

## Conditions studied

- Mucopolysaccharidosis (MPS)
- Hunter Syndrome

## Interventions

- **DRUG:** ELAPRASE
- **DRUG:** Rituximab
- **DRUG:** Methotrexate
- **DRUG:** Intravenous Immunoglobulin (IVIG)

## Key facts

- **NCT ID:** NCT05494593
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-02-28
- **Primary completion:** 2025-08-29
- **Final completion:** 2025-08-29
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study was closed due to enrollment challenges
- **Last updated:** 2025-12-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05494593

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05494593, "A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05494593. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*